IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Inclusion Criteria: * Histologically confirmed squamous CIN 3, or VIN 3 (usual type only) * The subject is either surgically sterile, postmenopausal, or agrees to practice an effective method of birth control as determined by the investigator (to be continued throughout the study period), except that subjects with CIN 3 are not permitted to use a cervical cap or diaphragm for contraception * White blood cell \> 2,500/ mcL (\> 2.5 x 10\^9/L) * Absolute neutrophil count \> 1,000/ microliter (\> 1 x 10\^9/L) * Platelet count \> 75,000/ mcL (\> 75 x 10\^9/L) * Hemoglobin \>= 8 g/dL (\>= 80 g/L) (subjects who have received a transfusion or erythropoietin up to one week prior to receiving the first dose of cyclophosphamide are eligible for the study) * International normalized ration (INR) or prothrombin time (PT) \< 1.5 x ULN (upper limit of normal) * Activated partial thromboplastin time (aPTT) \< 1.5 x ULN * Serum creatinine \< 1.5 x ULN * Total bilirubin \< 2.0 x ULN unless thought to be related to inherited bilirubin conjugation disorder (ie Gilbert?s disease) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN * The subject is geographically accessible for ongoing follow-up and is committed to comply with the designated visits * The subject is capable of understanding and complying with the protocol and has signed the enrollment informed consent form at screening Exclusion Criteria: * For subjects with cervical dysplasia: evidence of atypical…